Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302 | 0.82 | POLB (0.44) | CYP1A2CYP2D6CYP3A4MAOAMAOB | |
| SCHEMBL4071162 | 0.78 | ALDH1A1 (0.41) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL5463113 | 0.78 | ALDH1A1 (0.30) | ALDH1A1MAPK1 | |
| SCHEMBL4612770 | 0.78 | CYP1A2 (0.36) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL310210 | 0.78 | SOAT1 (0.36) | MAOAMAOBCA12CA1CA2 | |
| SCHEMBL310860 | 0.74 | SOAT1 (0.39) | MAOAMAOBALDH1A1RAB9ANPC1 | |
| SCHEMBL4615113 | 0.74 | CA2 (0.35) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL8728080 | 0.74 | CHRM2 (0.36) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL310542 | 0.73 | SOAT1 (0.41) | RAB9ANPC1 | |
| SCHEMBL2427059 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | claimed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | claimed |
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3169666-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-9580386-B2 | Substituted 4-aminocyclohexane derivatives | GRÜNENTHAL (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9403767-B2 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| WO-2016008582-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | Grünenthal GmbH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247573-A1 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247561-A1 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247591-A1 | SUBSTITUTED CYCLOHEXYLDIAMINES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| WO-2001027119-A2 | SUBSTANCE LIBRARY CONTAINING BICYCLIC IMIDAZO-5-YL-AMINES AND/OR BICYCLIC IMIDAZO-3-YL-AMINES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | CYP1A2 694/4885CYP2D6 549/4885CYP2C19 1888/4885 |
| US-20090247573-A1 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES | OPRL1, OPRM1, OPRD1 | CYP1A2 294/4885CYP2D6 250/4885CYP2C19 880/4885 |
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | CYP1A2 393/4885CYP2D6 715/4885CYP2C19 1931/4885 |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | OPRL1, OPRM1, OPRD1 | CYP1A2 420/4885CYP2D6 616/4885CYP2C19 1483/4885 |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | CYP1A2 278/4885CYP2D6 653/4885CYP2C19 2033/4885 |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | CYP1A2 393/4885CYP2D6 715/4885CYP2C19 1931/4885 |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | OPRL1, OPRD1, OPRM1 | CYP1A2 1012/4885CYP2D6 777/4885CYP2C19 1630/4885 |
| US-20090247591-A1 | SUBSTITUTED CYCLOHEXYLDIAMINES | OPRL1, OPRD1, OPRK1 | CYP1A2 783/4885CYP2D6 686/4885CYP2C19 1652/4885 |
| US-20090247561-A1 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | CYP1A2 789/4885CYP2D6 579/4885CYP2C19 1996/4885 |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | CYP1A2 46/4885CYP2D6 197/4885CYP2C19 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.